menu

The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma 

The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies   

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Related
Comments
  • Overview

    "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Caitlin Costello, MD
    Associate Clinical Professor of Medicine
    University of California, San Diego
    La Jolla, CA

    Dr. Costello has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AbbVie, BMS, Janssen, Karyopharm, Pfizer, Regeneron, Takeda
    Research: BMS, Harpoon, Ionis, Janssen, Pfizer, Poseida, Takeda

    Sagar Lonial, MD, FACP
    Chair and Professor
    Department of Hematology and Medical Oncology
    Anne and Bernard Gray Family Chair in Cancer
    Chief Medical Officer
    Winship Cancer Institute
    Emory University School of Medicine
    Atlanta, GA

    Dr. Lonial has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AbbVie, Amgen, BMS, Genentech, GSK, Janssen, Novartis, Pfizer, Regeneron

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Wilma Guerra has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Colleen Resnick has nothing to disclose. 
    • Mara Siegel has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify patients with relapsed and refractory multiple myeloma (RRMM) who are eligible to receive treatment with a bispecific antibody
    • Differentiate between bispecific antibodies that are FDA-approved for the treatment of RRMM
    • Recognize the adverse event profile of bispecific antibodies used for the treatment of RRMM
    • Employ strategies to prevent adverse events associated with bispecific antibody treatment for RRMM, including prophylaxis and step-up dosing, into treatment planning
  • Target Audience

    This activity is designed to meet the educational needs of hematology/oncology physicians, advanced practice providers, pathologists, emergency medicine physicians, hospitalists, and pharmacists. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until March 1, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour/0.1 CEUs of pharmacy contact hours.1 

    The Universal Activity Number for this program is JA0006235-0000-24-016-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an educational grant from Janssen Biotech Inc., administered by Janssen Scientific Affairs, LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule30 May 2024